Isabelle Boccon-Gibod
Isabelle Boccon-Gibod is an expert in Immunology at Centre Hospitalier Universitaire de Grenoble (France). As of October 2026, ScienceLeadR ranks Isabelle Boccon-Gibod in the top 1% of experts worldwide for Hypersensitivity and Skin Diseases, Vascular. Isabelle Boccon-Gibod has authored 178 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 2 of them ongoing. SLR score: 455 (community average: 125). How the SLR is computed.
LeadR Profile
Immunology
Subspecialties: Cardiology - Dermatology - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2009 - 2026
Number : 178
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Berotralstat Tolerability and Effectiveness in Hereditary Angioedema: Berolife Study Results. PMID 42603305 — pain, angioedemas, hereditary, therapeutics, angioedema, abdominal pain | Clin Transl Allergy | 2026 | 0 |
| [Not Available]. PMID 41967933 — hypersensitivity | Arerugi | 2026 | 0 |
| A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee. PMID 41766887 — quality of life, angioedemas, hereditary, algorithms, immune system diseases, therapeutics, angioedema | Front Immunol | 2026 | 0 |
| The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. PMID 41649409 — cells, hypersensitivity, urticaria, classification, work, diagnosis, therapeutics, angioedema, mast cells | Allergy | 2026 | 2 |
| International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema. PMID 41618059 — genetic testing, rare diseases, hypersensitivity, angioedemas, hereditary, signs and symptoms, bradykinin, diagnosis, therapeutics, angioedema | Allergy | 2026 | 0 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A 52 week multi center randomized double blind placebo controlled basket study with an open label extension to investigate the efficacy safety and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1 antihistamines 2023-505739-12-01 — histamine antagonists, safety, urticaria, multiple chronic conditions, chronic inducible urticaria | Phase 3 | Active not recruiting | 2024 |
| A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial 2025-524078-40-00 — urticaria, multiple chronic conditions, therapeutics | Phase 3 | Recruiting | 2026 |
LeadR Networks
Main global connection map